Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis
Lara Gracie, Yi Pan, Eshetu G. Atenafu, et al.
European Journal of Cancer (2021) Vol. 158, pp. 191-207
Open Access | Times Cited: 25

Showing 25 citing articles:

Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients
Zeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, et al.
Cancer (2023) Vol. 129, Iss. 11, pp. 1723-1734
Open Access | Times Cited: 34
Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases
Eftychia Chatziioannou, Jana Roßner, Thazin New Aung, et al.
EBioMedicine (2023) Vol. 93, pp. 104644-104644
Open Access | Times Cited: 23
The Use of Gene Expression Profiling and Biomarkers in Melanoma Diagnosis and Predicting Recurrence: Implications for Surveillance and Treatment
James Sun, Kameko M Karasaki, Jeffrey M. Farma
Cancers (2024) Vol. 16, Iss. 3, pp. 583-583
Open Access | Times Cited: 9
Circulating Tumor Cells and DNA in Early Diagnosis and Prognosis of Metastatic Cancer
Marium Jahan, A. Rubab, Mohsin Ali, et al.
IntechOpen eBooks (2025)
Closed Access | Times Cited: 1
Circulating Tumor DNA in High-Risk Stage II/III Cutaneous Melanoma: A Feasibility Study
Kristen E. Rhodin, Matthew O’Connor, Aaron D. Therien, et al.
Annals of Surgical Oncology (2025)
Closed Access
Predictive Factors for Sentinel Lymph Node Positivity in Melanoma Patients—The Role of Liquid Biopsy, MicroRNA and Gene Expression Profile Panels
Federico Venturi, Elisabetta Magnaterra, Biagio Scotti, et al.
Cancers (2025) Vol. 17, Iss. 8, pp. 1281-1281
Open Access
The Role of Cell-Free DNA in Cancer Treatment Decision Making
András Telekes, Anna Horváth
Cancers (2022) Vol. 14, Iss. 24, pp. 6115-6115
Open Access | Times Cited: 22
Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Li-Peng Liu, Su-Yu Zong, Ao‐Li Zhang, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 6, pp. 1143-1151
Closed Access | Times Cited: 4
Corresponding ctDNA and tumor burden dynamics in metastatic melanoma patients on systemic treatment
Michael E. Egger, Evan Alexander, Tracy L. Van Meter, et al.
Translational Oncology (2024) Vol. 42, pp. 101883-101883
Open Access | Times Cited: 4
Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
Andrea Gaißler, Jonas Bochem, Janine Spreuer, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 6, pp. e006802-e006802
Open Access | Times Cited: 10
Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers
Pavlina Spiliopoulou, Olga Vornicova, Sofia Genta, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1294-1294
Open Access | Times Cited: 9
IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients
Stefania Crucitta, Francesco Pasqualetti, Alessandra Gonnelli, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Early on-treatment assessment of T-cells, cytokines and tumor DNA with adaptively-dosed nivolumab + ipilimumab: final results from the phase 2 ADAPT-IT study
James W. Smithy, Hannah L. Kalvin, Fiona Ehrich, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 16, pp. 3407-3415
Closed Access | Times Cited: 3
Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma
Edoardo De Simoni, Francesco Spagnolo, Sara Gandini, et al.
Cancer Treatment Reviews (2024) Vol. 129, pp. 102788-102788
Closed Access | Times Cited: 2
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024
Claus Garbe, Teresa Amaral, Ketty Peris, et al.
European Journal of Cancer (2024) Vol. 215, pp. 115152-115152
Open Access | Times Cited: 2
Promising and Minimally Invasive Biomarkers: Targeting Melanoma
Pavlina Spiliopoulou, Carlos Diego Holanda Lopes, Anna Spreafico
Cells (2023) Vol. 13, Iss. 1, pp. 19-19
Open Access | Times Cited: 6
The Prognostic Value of a Single, Randomly Timed Circulating Tumor DNA Measurement in Patients with Metastatic Melanoma
Aurelio Boerlin, Elisa Bellini, Patrick Turko, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4158-4158
Open Access | Times Cited: 8
US physician perspective on the use of biomarker and ctDNA testing in patients with melanoma
Rachel A. Fischer, I. Ryan, Kristine De La Torre, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104289-104289
Open Access | Times Cited: 1
Circulating tumor DNA (ctDNA) application in investigation of cancer: Bench to bedside
Hashem O. Alsaab, Mohammad S. Alzahrani, Ammar Abdulraheem Bahauddin, et al.
Archives of Biochemistry and Biophysics (2024) Vol. 758, pp. 110066-110066
Closed Access | Times Cited: 1
Prognostic Biomarkers in Evolving Melanoma Immunotherapy
Robin Reschke, Alexander Enk, Jessica C. Hassel
American Journal of Clinical Dermatology (2024)
Open Access | Times Cited: 1
Unravelling Tumour Microenvironment in Melanoma at Single-Cell Level and Challenges to Checkpoint Immunotherapy
Xinyu Bai, Camelia Quek
Genes (2022) Vol. 13, Iss. 10, pp. 1757-1757
Open Access | Times Cited: 6
Serum cell‐free DNA as a new biomarker in cutaneous T‐cell lymphoma
Yuka Mizuno, S. Shibata, Tomomitsu Miyagaki, et al.
The Journal of Dermatology (2022) Vol. 49, Iss. 11, pp. 1124-1130
Closed Access | Times Cited: 4
Clinical and Imaging Follow-Up for High-Risk Cutaneous Melanoma: Current Evidence and Guidelines
John T. Vetto
Cancers (2024) Vol. 16, Iss. 14, pp. 2572-2572
Open Access
ctDNA-Analysen beim Melanom im adjuvanten und palliativen Stadium: Starker prognostischer Biomarker
Isabel Heidrich, Christoffer Gebhardt
Trillium Diagnostik (2023) Vol. 21, Iss. 3, pp. 175-179
Closed Access
Revisiting the Role of B-RAF Kinase as a Therapeutic Target in Melanoma
Paweł Kozyra, Monika Pitucha
Current Medicinal Chemistry (2023) Vol. 31, Iss. 15, pp. 2003-2020
Closed Access
Page 1

Scroll to top